Fischer H P, Meybehm M, Zhou H, Schoch J
Pathologisches Institut der Universität Bonn.
Verh Dtsch Ges Pathol. 1995;79:36-46.
Proliferation of preexisting bile ducts, ductular metaplasia of hepatocytes and proliferation and differentiation of liver stem cells are discussed in the pathogenesis of neoductular structures in the liver. Under the condition of experimental bile duct obstruction and in extrahepatic bile duct stenosis neoductular structures are first the result of proliferation and sprouting of preexisting ducts and cholangioles. Especially in later stages of cholestasis but also in other chronic progredient liver diseases such as chronic alcoholic liver disease and chronic active hepatitis periportal hepatocytes may show a phenotypic shift towards ductular epithelia. In postnatal liver diseases hepatocytes first express keratin 7 and later keratin 19 during ductular transdifferentiation. This is in contrast to embryonal cholangiogenesis. In alpha-1-antitrypsin-deficiency, hemochromatosis, Wilson's disease, and chronic active hepatitis B cellular deposites typically located in hepatocytes such as alpha-1-AT, siderin, copper, HBs-Ag, and HBc-Ag can also be found in neoductular cells close to hepatocytes. These deposites seem to be retained during the ductular transdifferentiation of hepatocytes. Expression of bile duct-type integrin subtypes and TGF beta 1 in neoductular cells are involved in the changing parenchymal/mesenchymal interplay during neoductogenesis, resulting in periductular basal membrane and periductular fibrosis. In FNH the ductular transdifferentiation of hepatocytes is integrated in the histogenesis of micronodules and portal tract equivalents of these tumor-like lesions. Ductular structures in hepatoblastomas and especially in combined hepatocellular and cholangiocarcinomas (CHCC) may reflect the common embryologic derivation of hepatocytes and biliary epithelia. Non-neoplastic liver tissue in resection specimens of our CHCC showed a lower rate of cirrhosis, and a significantly higher Ki 67-LI of neoductular cells compared to liver tissue in resection specimens of HCC and liver metastases. 3 of 10 CHCC had developed in alpha-1-AT-deficiency, in which this protease-inhibitor was predominantly retained in periportal hepatocytes. These findings in non-neoplastic tumor-bearing liver tissue suggest that CHCC include a special histogenic type of primary liver carcinoma which in analogy to some experimental liver tumors might develop from periportal parenchymal cells.
肝内新胆管结构的发病机制中讨论了原有胆管的增殖、肝细胞的小胆管化生以及肝干细胞的增殖和分化。在实验性胆管梗阻和肝外胆管狭窄的情况下,新胆管结构首先是原有胆管和胆小管增殖和出芽的结果。特别是在胆汁淤积的后期阶段,以及在其他慢性进行性肝病如慢性酒精性肝病和慢性活动性肝炎中,汇管区周围的肝细胞可能会出现向小胆管上皮细胞的表型转变。在出生后肝脏疾病中,肝细胞在小胆管转分化过程中首先表达角蛋白7,随后表达角蛋白19。这与胚胎期胆管生成不同。在α-1抗胰蛋白酶缺乏症、血色素沉着症、威尔逊病和慢性乙型活动性肝炎中,通常位于肝细胞内的细胞沉积物如α-1抗胰蛋白酶、含铁血黄素、铜、乙肝表面抗原和乙肝核心抗原,也可在靠近肝细胞的新胆管细胞中发现。这些沉积物似乎在肝细胞的小胆管转分化过程中得以保留。新胆管细胞中胆管型整合素亚型和转化生长因子β1的表达参与了新胆管形成过程中实质/间质相互作用的变化,导致胆管周围基底膜和胆管周围纤维化。在肝局灶性结节性增生中,肝细胞的小胆管转分化整合在这些肿瘤样病变的微结节和门管结构的组织发生过程中。肝母细胞瘤中的胆管结构,尤其是在肝细胞癌和胆管癌合并(CHCC)中的胆管结构,可能反映了肝细胞和胆管上皮细胞共同的胚胎学起源。我们的CHCC切除标本中的非肿瘤性肝组织显示肝硬化发生率较低,与HCC切除标本和肝转移瘤中的肝组织相比,新胆管细胞的Ki 67-LI显著更高。10例CHCC中有3例发生在α-1抗胰蛋白酶缺乏症中,在这种情况下,这种蛋白酶抑制剂主要保留在汇管区周围的肝细胞中。非肿瘤性肿瘤负荷肝组织的这些发现表明,CHCC包括一种特殊组织发生类型的原发性肝癌,类似于一些实验性肝肿瘤,可能起源于汇管区周围的实质细胞。